BioPharma Dive September 23, 2024
Sponsored content By Altasciences
Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight loss and reduction of atherosclerotic cardiovascular (CV) risk in patients with T2D.
The health benefits and market success of GLP-1 drugs are a hot topic in today’s pharmaceutical landscape. According to a MarketWatch report from February 2024, the global GLP-1 market is expected to reach $471 billion by 2032. As of February 2024, there were 15 GLP-1 medications approved by the FDA for glycemic and weight control, and more were already in development.
More than one billion people worldwide are living with obesity, which puts them at risk...
Today's Sponsors
Today's Sponsor